Cocktail-Solvent Screening to Enhance Solubility, Increase Crystal Yield, and Induce Polymorphs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Cocktail-Solvent Screening to Enhance Solubility, Increase Crystal Yield, and Induce Polymorphs
The authors propose extending initial solvent screening for a single-solvent system to the cocktail solvent screening of binary and ternary solvent mixtures.


Pharmaceutical Technology
Volume 32, Issue 1


Figure 5
Comparing the solubility of sulfathiazole Form III crystals in each solvent at 25 C (see Figure 3) with the solvent properties, the authors found that the dispersion-force contribution (Hansen dispersion parameter d) was small in all cases, but the polar-force contribution (Hansen polar parameter p) and the hydrogen-bonding contribution (Hansen hydrogen-bonding parameter h) were critical (24). The solvent needed relatively strong polar force, hydrogen bonding, or both to achieve acceptable solubility by disrupting the hydrogen-bonded network in crystalline sulfathiazole (9). This criterion is shown by the fact that the highest solubility was about 0.03 g/mL sulfathiazole Form III crystals in ternary solvent mixtures of acetonitrile, n-propanol, and water with mole fraction ratios of (45:10:45) (see Figure 6e) and (50:0:50) (see Figure 6a) at 25 C. Acetonitrile and water individually had high values of 18.0 MPa and 42.3 MPa for δp and δh at 25 C, respectively (24). Only when they were both blended at equally high mole fractions could the resultant mixed-solvent system exhibit relatively high solubility (see Figure 5). In this case, the solubility of the solvent mixtures (see Figure 5) was generally better than that of the single-solvent systems (see Figure 3).


Figure 6
Solids generated by the cooling method from the 11 good solvents (i.e., the yellow boxes in Table II) and 13 solvent mixtures (i.e., points 4–16 in Figure 2) were isolated and then analyzed by DSC and TGA. Although sulfathiazole forms solvates, TGA showed that none of the solids were solvates or hydrates because no weight loss occured from 50 to 205 C for all solids (19). Based on the five general melting points of Forms I–V sulfathiazole crystals at around 203, 198, 175, 166 (broad), and 148 C (broad), respectively, DSC responses in Figure 8 illustrated the various sulfathiazole crystal forms grown in the 11 single solvents: MEK (Forms I, III, and V), THF (Form III), acetone (Forms I and V), benzyl alcohol (Form I), acetonitrile (Forms I, III, and IV), n-propanol (Forms I and V), DMF (Form III), ethanol (Forms I, III, IV, and V), DMSO (Forms I, III, and V), methanol (Forms I, III, and V), and water (Forms I and III) (15).


Figure 7
Form II was not observed at all in any solvent. The endotherm at 203 C was the melting point of Form I, which might have been produced by the enantiotropic transformation of Forms II, III, IV (and possibly V) upon heating in the DSC (27). For example, a specimen of pure Form III generated in water that was free from seeds of Form I surpassed the transition point, melted at its melting point, and immediately underwent exothermic recrystallization, as indicated by the exotherm at about 182 C in Figure 8k. But sometimes crystals did not resolidify as polymorphs with higher melting points when the system was kinetically trapped, as in the cases of sulfathiazole solids grown in THF and DMF (see Figures 8b and 8g) (28, 29).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here